Novo Nordisk Lifts Forecast on Wegovy Pill's Strong Debut
Novo Nordisk raised its annual forecast following blockbuster demand for its new Wegovy pill, with first-quarter sales far exceeding market expectations.
Novo Nordisk raised its annual forecast following blockbuster demand for its new Wegovy pill, with first-quarter sales far exceeding market expectations.
Weight loss can restore heart muscle function in severe obesity by reversing protein changes linked to heart failure.
GLP-1 meds cause significant fat loss with minimal muscle loss over 12 months, proving their weight management efficacy.
GLP-1 study reports semaglutide preserved lean mass better than tirzepatide, with a 2% higher lean mass loss on tirzepatide over 12 months.
Turkey will start producing weight loss injections, Health Minister Kemal Memişoğlu announced, while emphasizing natural weight loss and addressing high C-section rates.